Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96FQ6

UPID:
S10AG_HUMAN

ALTERNATIVE NAMES:
Aging-associated gene 13 protein; Protein S100-F; S100 calcium-binding protein A16

ALTERNATIVE UPACC:
Q96FQ6; A8K439; D3DV52; Q5RHS6

BACKGROUND:
The S100 calcium-binding protein A16, with alternative names such as Aging-associated gene 13 protein and Protein S100-F, is identified for its calcium-binding capability, influencing one calcium ion per monomer. This protein is instrumental in adipocyte differentiation and has a profound effect on preadipocyte proliferation, adipogenesis, and insulin-mediated glucose uptake, suggesting its pivotal role in metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Protein S100-A16 offers a pathway to novel therapeutic interventions. Its critical role in regulating adipocyte behavior and glucose metabolism makes it a target of interest in the development of treatments for metabolic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.